Exagen (XGN) announced the appointment of Dr. Michael Mahler as Chief Scientific Officer. Over the course of his career, Dr. Mahler has held key positions at various diagnostic companies, most recently serving as Senior Vice President of Research Development and Business Development at Werfen. In his new role at Exagen, Dr. Mahler will spearhead strategic initiatives aimed at enhancing precision diagnostics for autoimmune diseases.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XGN: